Skip to main content

TNF-α Inhibition Reduces Echographic Abnormalities of PsA Enthesitis

For psoriatic arthritis (PsA), enthesitis is a key trait that echographic ultrasounds (US) is supported for the diagnosis of pre-clinical signs of enthesitis in asymptomatic patients at high risk for advanced forms.

Adalimumab was associated with a reduction in echographic abnormalities after 24 and 48 weeks of therapy for the treatment of psoriasis, according to the results of a study published in Journal of Dermatological Treatment.

A research group aimed to evaluate the effects of adalimumab on echographic and preclinical enthesitis signs in patients with plaque psoriasis. Enthesitis is a known sign of psoriatic arthritis (PsA), a disease known to affect approximately 30% of people with psoriasis.

In total, 49 patients with psoriasis were enrolled. Clinical and ultrasonographic examination of the hands, elbows, and knees was completed before patients were started on adalimumab. Additional clinical and ultrasonographic screening was performed after 24 and 48 weeks of treatment.

“We observed a reduction of the total number of echographic abnormalities and a significant decrease of the thickness of quadriceps tendons at week 24 and week 48,” wrote the study authors. “Furthermore, there was no evidence of significant articular damage progression during the entire study duration.”

The authors concluded that entheseal ultrasonography may be useful in for the preclinical diagnosis of PsA. Further, the study findings indicate that early detection and management with adalimumab leads to a block of articular damage progression. —Jessica Garlewicz

 

Reference
Narcisi A, Valenti M, De Simone C, et al. Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients. J Dermatolog Treat. Published online March 10, 2021. doi:10.1080/09546634.2021.1899112

Back to Top